作者
Jing Li,Hui Jin,Ying Zhang,周培媚,Yaoda Hu,Lianhua Zhang,Guangjie Jin,Yan Ding,Huibing Fu,Yaofei Wang,Guan Wang,Chengzhi Lv,Dakun Jin,Tao Chen,Jianjun Nie,Yan Chen,Qiao Peng,Yihui Yang,Meiwen Yu,Hongsheng Wang
摘要
BACKGROUND: Skin diseases have been identified as a public health priority at the 78th World Health Assembly, with a call for strengthened national surveillance and evidence-based responses. However, in China, comprehensive national epidemiological data on the prevalence of skin diseases have been lacking. We aimed to bridge this data gap by conducting the China Skin Health study, a large-scale, population-based, cross-sectional study. METHODS: In this study, we used a multistage stratified cluster random sampling design to obtain a nationally representative sample of adults aged 18 years or older from diverse geographical regions of China. We collaborated with provincial centres for disease control and prevention to establish a survey team comprising public health workers and ten to 12 certified dermatologists in each of the five provinces selected for the study. Residents' committees disseminated study information through posters and WeChat groups to recruit participants, and data were collected at local community health centres. Standardised electronic questionnaires were administered by trained interviewers to collect information on demographic and other characteristics. Certified dermatologists examined sun-exposed areas (eg, scalp, face, neck, and extremities) in all participants, as well as unexposed areas reported as concerns by respondents, for common skin diseases spanning 12 categories and more than 60 specific conditions. Clinical diagnoses were made on the basis of observed skin manifestations. The total number of skin conditions was recorded for each participant, and the mean number of skin conditions was calculated. Point prevalence of skin diseases was defined as the proportion of participants with a dermatologist-confirmed diagnosis of any listed condition at the time of the survey. Sampling weights derived from the study sampling framework and the 2020 National Population Census were applied when calculating prevalence and conducting logistic regression analyses. The absolute number of dermatological cases nationwide was estimated by applying prevalence estimates to the 2020 Chinese census data. FINDINGS: From July 1, 2022, to June 27, 2024, 153 593 participants completed the survey and were included in the analysis. The study population had a mean age of 48·5 years (SD 16·8), with 75 512 (49·2%) men and 78 081 (50·8%) women; 98 926 (64·4%) participants resided in urban areas. The age-standardised prevalence of skin diseases was 55·6% (95% CI 51·2-59·9), corresponding to an estimated 618 million (95% CI 567-666) affected adults in China, with a mean of 0·98 (SD 1·22) skin diseases per person. Prevalence increased with age, from 42·0% (95% CI 35·3-48·6) in those aged 18-29 years to 79·5% (75·8-83·1) in those aged 80 years or older (p<0·0001 for trend). Skin diseases were more common in women (56·5%, 51·8-61·1) than in men (54·6%, 50·5-58·7; p=0·023) and more prevalent in southern China (62·5%, 56·2-68·9) than in northern China (47·4%, 43·2-51·7; p<0·0001). Benign cutaneous tumours were the most prevalent type of condition (31·1%, 28·7-33·5), followed by superficial fungal infections (15·0%, 12·5-17·5); dermatitis, eczema, and allergic dermatoses (9·0%, 7·8-10·1); pigmentary dermatoses (7·9%, 6·3-9·6); and sebaceous and sweat gland dermatoses (5·7%, 5·0-6·4). Factors associated with skin diseases included female sex, increasing age, residence in southern China, current or former smoking, current or former alcohol consumption, overweight or obesity, a history of allergies, and a history of photosensitivity. Despite the substantial burden, only 5·8% (4·5-7·3) of affected individuals had sought medical care, and 18·2% (16·7-19·9) had used over-the-counter medications in the past year. INTERPRETATION: Skin diseases could affect more than half of Chinese adults. These findings highlight a substantial unmet need and should inform national priorities. FUNDING: National Key R&D Program of China, Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences, National Natural Science Foundation of China, and Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences.